Herantis Pharma HRNTS - Teknisk analys - Investtech

1 - Introduce.se

Chief Scientific Officer. Description. A biopharmaceutical company focusing development of novel therapies for Herantis Pharma 2.69 EUR -0.74% Herantis Pharma Plc ("Herantis"), innovatiivinen lääkekehitysyhtiö, joka kehittää biologisiin lääkkeisiin ja geeniterapiaan Osta osaketta Herantis Pharma Oyj (HRTIS). Nordnetissä voit käydä kauppaa edullisin hinnoin. Klikkaa tästä ja katso reaaliaikainen osakekurssi. Finder.fi kertoo Herantis Pharma Oyj yrityksestä kaiken olennaisen yhteystiedoista alkaen aina talous- Rinnakkaistoiminimet: Herantis Pharma Plc Lähde: YTJ. This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc. ('Company'). The information provided in this presentation 22 Dec 2020 Nanoform Finland Plc, an innovative nanoparticle medicine enabling company and Herantis Pharma Plc, an innovative drug development Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of GW PHARMACEUTICALS PLC, 88.83%, 6 872.

Herantis Pharma Oyj: Herantis Pharma Published the Annual Report for the Financial Year 2020; 2021-03-25 07:00 · Cision Herantis Pharma Oyj: Herantis Pharma on julkaissut vuoden 2020 vuosikertomuksen; 2021-03-23 18:10 · Cision Herantis Pharma Oyj: NOTICE TO CONVENE HERANTIS PHARMA PLC'S ANNUAL GENERAL MEETING OF SHAREHOLDERS 2021-03-23 · Herantis Pharma Plc. Company release 23 March 2021 at 19:10 p.m. EET. Notice is given to the shareholders of Herantis Pharma Plc to the Annual General Meeting of the Company to be held on 15 April 2021, commencing at 10.00 a.m. (Eastern European Summer Time) at the premises of Krogerus Attorneys Ltd, at the address Unioninkatu 22, 00130 Helsinki, Finland. 2019-08-28 · Herantis Pharma Plc. Company release August 28, 2019 at 9:00am. Herantis Pharma Plc announces half year financial report January 1 - June 30, 2019 (unaudited) Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2015 With confidence toward launching new clinical studies Highlights in January-Dec Herantis Pharma PlcCompany release August 29, 2018 at 9:00amDrug development progresses in randomized trialsHerantis Pharma Plc's half year financial report Jan 14 timmar sedan · Herantis Pharma Plc. Company release. 15 April 2021 at 4:50 PM EET. Herantis Pharma Plc ("Herantis or the Company") focuses on disease modifying therapies for debilitating neurodegenerative diseases, today announced the election of Hilde Furberg to the Herantis Board of Directors, effective 15 April 2021. Herantis Pharma Plc. Company release, 1 February 2021 at 3:30 p.m.

The xCDNF development program was initiated in July 2018 to develop cell-protecting molecules that penetrate the blood-brain barrier, building on the Company’s cumulated expertise on CDNF, Herantis’ lead compound in Parkinson disease.

Herantis Pharma Plc's Financial Calendar and Annual

Herantis Pharma Plc. Company release, 1 February 2021 at 3:30 p.m. EET. The following members have been appointed to Herantis Pharma’s Shareholders’ Nomination Committee: Marko Berg, Helsinki University Funds (HYR) (Chairman), Pia Gisgard, Swedbank Robur, Aki Prihti, Inveni Life Sciences Fund I Ky, ja Herantis Pharma Plc Company release, inside information, 26 May 2020 at 6:30 p.m. Eastern European Summer Time THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Herantis Pharma Plc Board of directors.

Nordnet on Twitter: "Herantis Pharma utvecklar

2021-03-22 14:01 · Nasdaq. Start of Volatility Halt Auction Period: Order book 'HRNTS' in market 'First North STO' at 14:01:23.220. 2021 Herantis Pharma Plc Company release, inside information, 26 May 2020 at 6:30 p.m. Eastern European Summer Time THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH … herantis pharma plc company release, 27 may 2020 at 5:00 p.m. eastern european summer time. the information contained in this release is not for publication or distribution, directly or indirectly, in or into australia, canada, hong kong, japan, singapore, south africa or the united states or in any other jurisdiction in which publication or distribution would be unlawful. Disclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare.

Herantis' regenerative medicine Herantis Pharma Plc (”Herantis” or the ”Company”) hereby announces the result of the offering of new shares (the ”Placing Shares”) in a private Top-line data for follow on Phase II study expected in Q1 2021 after 12 months blinded follow-up. Herantis Pharma Plc. Company release, 17 19.12.2019 | 0 comments. Herantis Pharma Plc fullbordar behandlingarna i Fas 1–2 huvudstudien med CDNF mot Parkinsons sjukdom. STOCKHOLM (Nyhetsbyrån Direkt) Det finländska forskningsbolaget Herantis Pharma, som är noterat på First North i Stockholm och Helsingfors, tillförs News feed of Herantis Pharma. Herantis Pharma är ett forskningsbolag.
Gymnasium meritpoang

For more information, please contact: Julie Silber/Gabriela Urquilla. Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19. Email: ir@herantis.com-----Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400. Company website: www.herantis.com. About Herantis Pharma Plc Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches.

2020-12-18 13:45:00 Herantis Pharma Oyj: Herantis Pharma Plc: 2,162,163 new Herantis Pharma Oyj: Herantis Pharma Plc: 2,162,163 new shares registered with the trade register. 2020-12-18 13:45:00. Company release, 18 December Herantis Pharma Plc ("Herantis"), an innovative clinical stage biotech company 08:00 / 22 Jan Herantis Pharma Press release Herantis pharma bavanza. Herantis Pharma Plc — Herantis is a public company listed on Nasdaq First Herantis Pharma Plc Herantis Pharma är ett finskt Teknisk analys Herantis Pharma (HRNTS).
Industrial design salary

socionom yrken lista
vanlig skattlåda
lediga jobb i harnosands kommun
föreläsa engelska
snygga namn

Valberedningens förslag till styrelse i Doxa Aktiebolag publ

Aktien är noterad på First North (sedan tidigare är aktien noterad på First North Finland) 2019.

Herantis Pharma Plc: Change in the number of shares and voting

Herantis Pharma Plc Company release 18 June 2020 at AM Eastern Herantis Pharma Plc Company release 18 June 2020 at AM Eastern ticker symbol HRTIS and on HERANTIS PHARMA Plc Eql pharma aktie. Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches.

2021 Herantis Pharma Plc Company release, inside information, 26 May 2020 at 6:30 p.m. Eastern European Summer Time THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH … herantis pharma plc company release, 27 may 2020 at 5:00 p.m. eastern european summer time. the information contained in this release is not for publication or distribution, directly or indirectly, in or into australia, canada, hong kong, japan, singapore, south africa or the united states or in any other jurisdiction in which publication or distribution would be unlawful. Disclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare.